Arrowhead Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:ARWR)

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) posted its earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.18) EPS for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $0.73 million for the quarter, compared to analysts' expectations of $0.62 million. Arrowhead Pharmaceuticals had a return on equity of 26.27% and a net margin of 33.28%. View Arrowhead Pharmaceuticals' Earnings History.

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 25th 2019. View Earnings Estimates for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals will be holding an earnings conference call on Monday, November 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

5 analysts have issued twelve-month price objectives for Arrowhead Pharmaceuticals' shares. Their forecasts range from $24.00 to $59.00. On average, they expect Arrowhead Pharmaceuticals' stock price to reach $44.20 in the next twelve months. This suggests that the stock has a possible downside of 8.2%. View Analyst Price Targets for Arrowhead Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals.

News articles about ARWR stock have trended neutral this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a news impact score of 0.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals saw a drop in short interest in October. As of October 15th, there was short interest totalling 14,810,000 shares, a drop of 7.5% from the September 15th total of 16,010,000 shares. Based on an average daily volume of 1,400,000 shares, the days-to-cover ratio is presently 10.6 days. Currently, 16.8% of the shares of the company are short sold. View Arrowhead Pharmaceuticals' Current Options Chain.

Some companies that are related to Arrowhead Pharmaceuticals include Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Beigene (BGNE), Mylan (MYL), Ionis Pharmaceuticals (IONS) and Amarin (AMRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Micron Technology (MU), AbbVie (ABBV), Alibaba Group (BABA), Sasol (SSL), salesforce.com (CRM), Walt Disney (DIS), Sarepta Therapeutics (SRPT) and Bank of America (BAC).

Arrowhead Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include California Public Employees Retirement System (0.30%), Rhumbline Advisers (0.30%), First Trust Advisors LP (0.15%), New York State Teachers Retirement System (0.14%), Bailard Inc. (0.11%) and Comerica Bank (0.09%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

ARWR stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, First Trust Advisors LP, Bailard Inc., Mackay Shields LLC, Meeder Asset Management Inc., Vanguard Capital Wealth Advisors, Creative Planning and First Quadrant L P CA. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, William D Waddill and Zhen Li. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

ARWR stock was purchased by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, State of New Jersey Common Pension Fund D, Moody Lynn & Lieberson LLC, SG Americas Securities LLC, State of Alaska Department of Revenue, California Public Employees Retirement System, Texas Permanent School Fund and Arlington Capital Management Inc.. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARWR stock can currently be purchased for approximately $48.17.

Arrowhead Pharmaceuticals has a market capitalization of $4.57 billion and generates $16.14 million in revenue each year. The biotechnology company earns $-54,450,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.View Additional Information About Arrowhead Pharmaceuticals.

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]